Science & Enterprise subscription

Follow us on Twitter

  • Researchers in Finland are designing techniques using temperature-controlled lasers to treat a common form of visio…
    about 12 hours ago
  • New post on Science and Enterprise: Laser Treatments Developed for Age-Related Vision Loss #Science #Business
    about 12 hours ago
  • Drug maker Sanofi and Alphabet, the parent company of Google, are collaborating on the use of artificial intelligen…
    about 16 hours ago
  • New post on Science and Enterprise: Sanofi, Alphabet Partner on A.I., Analytics #Science #Business
    about 16 hours ago
  • A challenge competition is seeking new businesses that disrupt the plastics recycling and energy storage industries…
    about 1 day ago

Please share Science & Enterprise

Spirogen, Genentech Partner on Anti-Cancer Therapies

Beakers and test tubes (Horia Varlan/Flickr)Spirogen Ltd. a London, U.K. biotechnology company, announced a multi-year research collaboration and license agreement with Genentech, a Roche Group company, to discover and develop antibody drug conjugates (ADCs) as potential anti-cancer agents.

The collaboration will make use of Spirogen’s pyrrolobenzodiazepine (PBD) drugs,  a group of natural antibiotics, and associated linking technology. Under the agreement, Spirogen will synthesize and manufacture drug reagents, while Genentech will use Spirogen’s drug reagents to generate ADCs and evaluate their therapeutic potential. Genentech will have an exclusive license to fully develop and commercialize licensed products that contain these ADCs.

Terms of the multi-year collaboration include an initial one-time license fee, development milestones on reaching pre-defined targets, and further milestones and royalties for licensed products. The amounts of those payments were not disclosed.

Photo: Horia Varlan/Flickr

*     *     *

Please share Science & Enterprise ...

2 comments to Spirogen, Genentech Partner on Anti-Cancer Therapies